Market revenue in 2023 | USD 64.9 million |
Market revenue in 2030 | USD 183.7 million |
Growth rate | 16% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.58% in 2023. Horizon Databook has segmented the France crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Strategic initiatives undertaken by French biotechnology and agri-biotech companies to increase penetration of CRISPR gene editing technology are expected to boost revenue generation of the country’s market.
Under this agreement, Vilmorin & Cie received a license to access CRISPR-Cas9 patents of Corteva that covered genome editing tools for agricultural use. This allowed Vilmorin & Cie to deploy it in vegetable and field seeds-related research work & commercial applications.
Such initiatives have strengthened the company’s ability to develop more efficient seed varieties, consequently, expanding the usage of CRISPR technology across the French agriculture industry. Moreover, numerous patent approvals by regulatory agencies are expected to drive the importance of CRISPR technology in France.
Horizon Databook provides a detailed overview of country-level data and insights on the France crispr and cas genes market , including forecasts for subscribers. This country databook contains high-level insights into France crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account